Medivation Inc. (MDVN): Today's Featured Health Care Mover

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Medivation ( MDVN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.7%. By the end of trading, Medivation rose 94 cents (1.8%) to $54.74 on average volume. Throughout the day, 1.2 million shares of Medivation exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in a price between $52.98-$54.92 after having opened the day at $53.90 as compared to the previous trading day's close of $53.80. Other companies within the Health Care sector that increased today were: Acura Pharmaceuticals ( ACUR), up 34%, Oragenics ( OGEN), up 25.4%, Oragenics ( ORNI), up 25.4%, and Alkermes ( ALKS), up 16.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $3.97 billion and is part of the drugs industry. Shares are up 5.2% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Medivation a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow.

On the negative front, Urologix ( ULGX), down 11.1%, Tianyin Pharmaceutical ( TPI), down 9.5%, China Pharma ( CPHI), down 9.3%, and LCA-Vision ( LCAV), down 8.5%, were all laggards within the health care sector with Cigna ( CI) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors